Kelyniam Global, Inc. operates as a medical device manufacturing company, which engages in the production of custom prosthetics utilizing computer aided design and computer aided manufacturing of advanced medical grade polymers. The company is headquartered in Canton, Connecticut. The company went IPO on 2008-04-03. The firm is engaged in the production of custom prosthetics utilizing computer-aided design and computer-aided manufacturing of medical-grade polymers. Its Engineering Division uses Bio-Computer Aided Design (CAD) Computer Aided Manufacturing (CAM) technology to provide replicated cranial implants to replace damaged bone structures. Its product, PEEK-Optima, is engineered for biocompatibility. Derived from the patient’s computed tomography (CT) data, its 3D BIO-CAD/CAM software is used to transfer the details found on the edge of the defect directly to the implant edge. Its emergency plan, ke24, provides precision-replicated, patient-specific cranial implants in approximately 24 hours. The company distributes its products throughout the United States via independent distributors and sales representatives.
KLYG stock price ended at $0.14 on 月曜日, after rising 16.67%
On the latest trading day Feb 09, 2026, the stock price of KLYG rose by 16.67%, climbing from $0.13 to $0.14. During the session, the stock saw a volatility of 7.69%, with prices oscillating between a daily low of $0.13 and a high of $0.14. Notably, trading volume dropped by 8.9K shares on the last day despite the price increase, which may signal a potential uptick in risk in the near term. A total of 10.4K shares were traded, equating to a market value of approximately $7.0M.